Matches in Nanopublications for { ?s ?p ?o <http://www.tkuhn.ch/bel2nanopub/RAz_MjdVcD8T499wbPlljbSwdErFHp-G1PTa__8SV7T24#provenance>. }
Showing items 1 to 11 of
11
with 100 items per page.
- _7 label "Selventa" provenance.
- large_corpus.bel title "BEL Framework Large Corpus Document" provenance.
- large_corpus.bel description "Approximately 61,000 statements." provenance.
- large_corpus.bel version "20131211" provenance.
- large_corpus.bel authoredBy _7 provenance.
- assertion wasDerivedFrom large_corpus.bel provenance.
- assertion wasDerivedFrom _6 provenance.
- assertion hadPrimarySource 15864276 provenance.
- _6 wasQuotedFrom 15864276 provenance.
- _6 value "More recently, ERBB transactivation has been shown to involve other physiological ligands (FIG. 2). The binding of WNT to its seven-pass membrane receptor Frizzled (FZD) transactivates EGFR. The mechanism seems to be similar to that described for GPCRs, as it is rapid and blocked by metalloproteinase inhibitors; however, the target ligand has not been identified. WNT?FZD-mediated transactivation has been observed in normal mammary cells43 and in breast cancer cells (T. Schlange and N.E.H., unpublished observations). Oestradiol (E2) bindingto plasma-membrane-associated oestrogen receptor (ER) has also been shown to rapidly transactivate ERBBs. According to one report, E2-stimulated activation of MMP2 and MMP9 leads to the release of HB-EGF. Tamoxifen, a selective ER modifier (SERM) was shown to transactivate EGFR and ERBB2, and in ERBB2-overexpressing breast cancer cells this reduced the antiproliferative activity of the SERM" provenance.
- large_corpus.bel rights "Copyright (c) 2011-2012, Selventa. All rights reserved." provenance.